A placebo-controlled trial of d-fenfluramine in bulimia nervosa.
d-Fenfluramine is a 5-HT agonist which decreases food intake and excessive carbohydrate intake in humans. A placebo-controlled trial of d-fenfluramine (45 mg/day) was conducted in 43 patients with bulimia nervosa. The patients entered an eight-week trial of medication during which they also received cognitive-behavioural therapy. Treatment response was assessed using food diaries to record eating behaviour, and self-rating questionnaires to measure psychopathology. The drug trial, and a follow-up assessment after a further eight weeks, were completed by 39 patients. Abnormal eating behaviour and psychopathology improved significantly in both the d-fenfluramine and placebo groups during the treatment trial. The study failed to show that the addition of d-fenfluramine affords an advantage over brief psychotherapy alone. Although d-fenfluramine is effective in suppressing the overeating, excessive snacking, and excessive carbohydrate consumption which are frequently found in overweight or obese patients, this study suggests that the drug is not an effective treatment for bulimia nervosa.
Fahy
T A
TA
King's College Hospital, London.
Eisler
I
I
Russell
G F
GF
D000293:Adolescent; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D002032:Bulimia / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D015928:Cognitive Behavioral Therapy; D003131:Combined Modality Therapy; D005247:Feeding Behavior / Q000187:drug effects; D005260:Female; D005277:Fenfluramine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012701:Serotonin / Q000378:metabolism; D012720:Severity of Illness Index; D016896:Treatment Outcome
D010919:Placebos; D005277:Fenfluramine; D012701:Serotonin